Martin Shkreli

Tommy the Hamburger is here again, and this is Historical Depravity, where we dig up the polished bones of history, crack them open, and show you the rot they tried to dress up as greatness. They called these people kings, visionaries, captains of industry, patriots, reformers, whatever flattering bullshit helped the blood dry faster. I'm here to show you what they actually were. Martin Shkreli got packaged as a meme villain so fast it almost saved the real system from scrutiny. Smirking asshole. Hoodie finance goblin. Pharma Bro. Human sneer with a Twitter account. The mythology around him is weirdly flattering in its own ugly way because it turns him into a freak exception, the one outrageous bastard who took drug greed too far and was punished for it. That story lets everybody else in the machine breathe easy. It says the problem was one loud mouth with bad hair and sociopath energy, not a healthcare economy designed to let men like him make fortunes by cornering suffering. That is bullshit. Shkreli belongs here not because he invented pharmaceutical extortion, but because he made its logic impossible to ignore. He took an old generic drug used by people with compromised immune systems, grabbed the rights, and hiked the price so violently that the whole country had to stare at the thing American medicine usually tries to hide in accounting language. He did not expose a broken system by accident. He exploited it on purpose, with a grin, because he knew the rules were built to protect extraction long before they were ever built to protect patients. Myth says Martin Shkreli was a uniquely evil troll who embarrassed an otherwise respectable industry. Reality says he was a loud, smug, chemically pure expression of what that industry already rewards: monopoly control, desperation pricing, legal sadism, and the conversion of illness into leverage. He was not the disease. He was one of the clearer symptoms. The file everyone remembers is Daraprim. That is the hook because the number was so obscene it punched through the public haze. Daraprim, a decades old drug used to treat toxoplasmosis, especially dangerous for people with AIDS and other compromised immune systems, went from roughly thirteen dollars and change a pill to seven hundred fifty dollars a pill after Shkreli's company acquired the rights. The percentage jump was so cartoonishly filthy that it made headlines instantly. But the jump itself was not some random fit of insanity. It was strategy. That is the first thing to understand. This was not a man losing his temper in a boardroom. This was a business model. Find a drug with a captive or small patient population. Get control. Limit practical alternatives. Jack the price because the people who need it are too sick, too trapped, or too structurally powerless to negotiate. That is not innovation. That is hostage taking with corporate paperwork. Fuck me sideways, that is what makes this story so rancid. The product is not luxury. The product is not convenience. The product is not some stupid little subscription people can cancel when the monthly bill gets annoying. The product sits in the corridor between a vulnerable body and a worse outcome. Once you understand that, every sentence about shareholder value starts sounding like grave dirt in a necktie. And Shkreli was brazen enough to say the quiet part out loud. That is one reason the class turned on him. He lacked the polished hypocrisy that usually protects this sort of predation. Plenty of pharmaceutical executives will bleed people dry while talking about access, innovation, sustainability, and hard choices in the face of market realities. Shkreli often just sounded like a little shit who knew he had leverage and loved it. Same extraction. Worse manners. America forgives cruelty much more easily than it forgives vulgarity. That distinction matters because his public image became a useful decoy. If you stare too long at the smirk, you stop examining the structure underneath it. You stop asking why the law allowed the move. You stop asking why lifesaving or life preserving drugs can become chips in a speculative game. You stop asking why public outrage produces hearings and sound bites while the core price mechanics keep chugging along untouched. Shkreli gave the country a villain face, and the country almost thanked him by refusing to look behind it. The investor fraud side of his life matters too, because it rounds out the picture. He was not merely a price gouging ghoul; he was also a liar with a long appetite for using other people's money like it belonged to him. His hedge fund history and the securities case that eventually put him behind bars showed the same basic operating instinct: keep the performance alive, manipulate the story, juggle the obligations, bullshit the people who trusted you, and assume that confidence can outrun collapse. Different arena, same rot. That continuity is important. The lesson is not that a decent businessman tragically discovered the incentives of pharma and went bad. The lesson is that Shkreli kept turning up in systems where arrogance, opacity, and asymmetrical power made fraud or predation easier than honesty. He had the temperament for it, sure, but the systems were practically laid out like a banquet table for people with his exact appetites. And the victims were not abstract. Daraprim was used by people who were already medically cornered. Patients with weakened immune systems. Doctors trying to treat infections that can get catastrophic fast. Hospitals facing sudden cost explosions. Insurers passing costs onward. Public programs eating inflated bills. The pain moved outward in layers. Some patients scrambled for assistance. Some institutions rationed or fought over procurement. Some clinicians had to burn time and energy trying to navigate the financial nonsense wrapped around a medication that had already existed for decades. That is the hidden brutality of this kind of depravity. It steals not only money, but time, attention, trust, and margin for people who were already under pressure. The media liked telling the story as though Shkreli was some deranged one man outburst against decency. That framing was emotionally satisfying because it let everybody boo one face. But if you follow the actual machinery, the deeper indecency is how normal so much of it was. Closed distribution systems. Orphan drug games. Patent tricks. Exclusivity abuse. Strategic acquisition of old drugs. Market capture through legal and regulatory channels rather than scientific achievement. Shkreli did not invent the playbook. He just read from it in a voice too nasty to ignore. And then there is the American obsession with the smart asshole. This country keeps half falling in love with men who weaponize contempt and call it brilliance. If the bastard is young, fast talking, financially fluent, and visibly amused by social norms, some people decide that must mean he sees reality more clearly than the rest of us. Shkreli exploited that too. He turned irony, trolling, and deliberate offensiveness into part of the shield. He made public disgust look like proof he was operating at some higher cynical level. But there was nothing deep there. No grand theory. No misunderstood genius. Just a greedy prick treating human need like a pricing advantage. That is why the Wu Tang album stunt felt so perfect and so disgusting at the same time. It was not central to the actual material harm, but it exposed his emotional geometry. Scarcity, possession, exclusivity, taunting the crowd, buying something priceless just to control access and enjoy the public's frustration. Same rhythm. Same little god complex. Whether it was medicine or music, the thrill was in owning the choke point and making everyone else feel it. But here is where the file gets even dirtier. The legal system did eventually punish him, but not cleanly for the thing that made him a household monster. He went down on securities fraud. That mattered and it was real, but notice the shape of the lesson. Defraud investors and the state gets sharper elbows. Corner a medical necessity and legally bleed patients, and suddenly the system grows philosophical about markets, innovation, and complicated pricing dynamics. That is a moral x ray of the whole arrangement. Capital gets cleaner protection than sick people do. The point is not that investor fraud is harmless. It is not. The point is that the contrast tells you what the machine values. One kind of theft is treated as a violation of the sacred order. The other gets routed through policy debate, lobbying, and sterile language while actual human beings wonder whether they can afford what keeps them alive. That is not an accident. That is design. And yes, Shkreli's open smirk made him easy to hate. Good. He was easy to hate. But hatred can get lazy if it stops at the surface. The deeper file is that the pharmaceutical industry has long depended on a moral laundering service. It calls monopoly exploitation research incentive. It calls extortion market correction. It calls public desperation a pricing environment. It hires enough respectable faces to make obscene conduct sound like a regrettable but necessary part of preserving future cures. Shkreli stripped some of that language off by being too vulgar to finish the sentence politely. That is why people still bring him up whenever drug pricing comes back into the news. He has become shorthand. But shorthand can reduce the truth if you are not careful. The real lesson is not just don't be like Pharma Bro. The real lesson is that if the law permits essential medicines to become extraction engines, then the next Shkreli does not even need to be a troll. The next one can be well dressed, media trained, charitable in tone, and still do broadly the same filthy thing with better manners and softer press coverage. He also matters because he blew apart the fantasy that markets naturally self correct where medicine is concerned. Sick people are not shopping for sneakers. Doctors do not prescribe around monopoly abuse as easily as consultants talk about consumer choice. Patients in crisis do not form beautiful little price disciplined markets. They get trapped. And the more trapped they are, the more attractive they become to predators who can seize the bottleneck. That is the mechanism under the whole damn thing: dependence plus scarcity plus legal control equals a chance to convert suffering into margin. Once you see it clearly, the sanitizing language starts sounding insane. There is nothing noble about it. Nothing efficient in the moral sense. Nothing admirable about a system that teaches executives and speculators to see vulnerable patients as proof of pricing power. So file Martin Shkreli correctly. File him not as a lone monster who somehow wandered in from outside civilized capitalism, but as a loud, sneering concentration of incentives already embedded inside American pharmaceutical finance. File Daraprim not as one freak outrage, but as a brutally clear case of how monopoly medicine turns illness into leverage. File his fraud record, his trolling, and his public grin as style notes on top of the deeper offense: the treatment of human medical dependency as a business opportunity. That is the depravity on record. The myth is smaller now, the stink is stronger, and the body count is still the body count. See you in the next grave I have to dig up.